Novartis is trialling artificial intelligence (AI) in settings across drug discovery and drug development to help its scientists improve decision making.
ESMO 2024 was chock full of oncological data, diverse presentations providing hope across the cancer spectrum from breast and lung to unmet needs in colorectal and bladder.